© 2022 MJH Life Sciences™ and HCPLive - Clinical news for connected physicians. All rights reserved.
February 07, 2020
RBX2660 from Rebiotix will be assessed in a randomized study involving 300 patients.
January 23, 2020
New data for the 2019-2020 season shows the virus is at a high activity, but disease severity is moderate.
November 15, 2019
In the pivotal assessment, three-quarters of patients who received cefiderocol had resolution of symptoms and eradication of the bacteria 1 week after completing treatment, versus 54.6% of patients who received an alternative antibiotic.
October 26, 2019
The supplemental new drug application was approved based on results of a phase 3 trial in which IV-to-oral delafloxacin met the primary end point of statistical non-inferiority to moxifloxacin.
Jennifer Green, MD: Outcomes, Impact of SGLT2i, GLP-1 RA Combination Therapy
Joshua J. Joseph, MD: Managing CV Risk Factors in Patients with Type 2 Diabetes
Antirituximab Antibodies Detected in Patients with Pemphigus